231 related articles for article (PubMed ID: 20580216)
1. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD.
Berton DC; Reis M; Siqueira AC; Barroco AC; Takara LS; Bravo DM; Andreoni S; Neder JA
Respir Med; 2010 Sep; 104(9):1288-96. PubMed ID: 20580216
[TBL] [Abstract][Full Text] [Related]
2. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
[TBL] [Abstract][Full Text] [Related]
3. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD.
Worth H; Förster K; Eriksson G; Nihlén U; Peterson S; Magnussen H
Respir Med; 2010 Oct; 104(10):1450-9. PubMed ID: 20692140
[TBL] [Abstract][Full Text] [Related]
4. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
Beeh KM; Korn S; Beier J; Jadayel D; Henley M; D'Andrea P; Banerji D
Respir Med; 2014 Apr; 108(4):584-92. PubMed ID: 24534204
[TBL] [Abstract][Full Text] [Related]
5. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
[TBL] [Abstract][Full Text] [Related]
6. Addition of tiotropium to formoterol improves inspiratory muscle strength after exercise in COPD.
Canto ND; Ribeiro JP; Neder JA; Chiappa GR
Respir Med; 2012 Oct; 106(10):1404-12. PubMed ID: 22748747
[TBL] [Abstract][Full Text] [Related]
7. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD.
Terzano C; Petroianni A; Conti V; Ceccarelli D; Graziani E; Sanduzzi A; D'Avelli S
Respir Med; 2008 Dec; 102(12):1701-7. PubMed ID: 18760583
[TBL] [Abstract][Full Text] [Related]
8. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease.
Casaburi R; Maltais F; Porszasz J; Albers F; Deng Q; Iqbal A; Paden HA; O'Donnell DE;
Ann Am Thorac Soc; 2014 Nov; 11(9):1351-61. PubMed ID: 25289942
[TBL] [Abstract][Full Text] [Related]
9. Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD.
Guenette JA; Raghavan N; Harris-McAllister V; Preston ME; Webb KA; O'Donnell DE
Respir Med; 2011 Dec; 105(12):1836-45. PubMed ID: 21917440
[TBL] [Abstract][Full Text] [Related]
10. Effects of formoterol on exercise tolerance in severely disabled patients with COPD.
Neder JA; Fuld JP; Overend T; Thirlwell J; Carter R; Stevenson R; Ward SA
Respir Med; 2007 Oct; 101(10):2056-64. PubMed ID: 17658249
[TBL] [Abstract][Full Text] [Related]
11. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.
van Noord JA; Aumann JL; Janssens E; Verhaert J; Smeets JJ; Mueller A; Cornelissen PJ
Chest; 2006 Mar; 129(3):509-17. PubMed ID: 16537846
[TBL] [Abstract][Full Text] [Related]
12. Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study.
Berton DC; Santos ÁH; Bohn I; Lima RQ; Breda V; Teixeira PJ
J Bras Pneumol; 2016; 42(5):367-373. PubMed ID: 27812637
[TBL] [Abstract][Full Text] [Related]
13. [The influence of treatment with formoterol, formoterol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and simple, morning everyday activities in patients with chronic obstructive pulmonary disease (COPD)].
Szmidt M
Pneumonol Alergol Pol; 2012; 80(3):255-62. PubMed ID: 22562275
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender.
Tashkin DP; Varghese ST
Pulm Pharmacol Ther; 2011 Feb; 24(1):147-52. PubMed ID: 20659577
[TBL] [Abstract][Full Text] [Related]
16. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.
Tashkin DP; Pearle J; Iezzoni D; Varghese ST
COPD; 2009 Feb; 6(1):17-25. PubMed ID: 19229704
[TBL] [Abstract][Full Text] [Related]
17. Effect of combination treatment on lung volumes and exercise endurance time in COPD.
Magnussen H; Paggiaro P; Schmidt H; Kesten S; Metzdorf N; Maltais F
Respir Med; 2012 Oct; 106(10):1413-20. PubMed ID: 22749044
[TBL] [Abstract][Full Text] [Related]
18. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.
Casaburi R; Kukafka D; Cooper CB; Witek TJ; Kesten S
Chest; 2005 Mar; 127(3):809-17. PubMed ID: 15764761
[TBL] [Abstract][Full Text] [Related]
19. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study.
Vogelmeier C; Kardos P; Harari S; Gans SJ; Stenglein S; Thirlwell J
Respir Med; 2008 Nov; 102(11):1511-20. PubMed ID: 18804362
[TBL] [Abstract][Full Text] [Related]
20. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.
Tashkin DP; Donohue JF; Mahler DA; Huang H; Goodwin E; Schaefer K; Hanrahan JP; Andrews WT
Respir Med; 2009 Apr; 103(4):516-24. PubMed ID: 19208459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
